Suramin Sodium Salt

ArtNr	TMO-T2160-200mg
Hersteller	TargetMol
CAS-Nr.	129-46-4
Menge	200 mg
Quantity options	100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mg 200 mg 25 mg 2 mg 50 mg 5 mg
Kategorie	Reagents & Chemicals Molecules
Typ	Molecules
Specific against	other
Purity	0,998
Citations	1. Klinger M, et al. Biochem J. 2001 May 1;355(Pt 3):827-33.
Smiles	[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	BAY-205,Suramin hexasodium salt,NF-060
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Targets	Sirtuin\|\|\|Parasite\|\|\|Reverse Transcriptase\|\|\|Apoptosis\|\|\|Phosphatase\|\|\|SARS-CoV\|\|\|Topoisomerase
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	1429.15
Description	Suramin Sodium Salt (BAY-205) is a sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.
Pathways	DNA Damage/DNA Repair\|\|\|Microbiology/Virology\|\|\|Chromatin/Epigenetic\|\|\|Apoptosis\|\|\|Metabolism
Bioactivity	Suramin Sodium is a sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.
Receptor	Topo II

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

TMO-T2160-200mg-datasheet.pdf

Sicherheitsdatenblatt anfordern

Einfache Bestellung Periodische Bestellung

Menge: 200 mg

lieferbar

Technische Frage stellen